QuartrQuartr

PharmaEssentia: H1 2026 saw robust revenue and profit growth, major acquisition, and ongoing legal disputes

Meno di 1 minuto di lettura

Revenue and net income surged year-over-year for the first half of 2026, driven by strong product sales and global expansion. The acquisition of Forus Therapeutics Inc. and ongoing legal proceedings with AOP Orphan Pharmaceuticals GmbH were key events impacting results.

Original document: PharmaEssentia Corp. [6446] Interim report — Aug. 12 2026

Declinazione di responsabilità